Dec 24 (Reuters) - Biohaven (BHVN.N), opens new tab said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback